View in EDS HTML Full Text PDF Full Text

Nicho terapéutico de ceftazidima-avibactam frente a bacterias gramnegativas resistentes a carbapenémicos en Colombia.

Saved in:
Bibliographic Details
Title: Nicho terapéutico de ceftazidima-avibactam frente a bacterias gramnegativas resistentes a carbapenémicos en Colombia.
Alternate Title: Therapeutic niche of ceftazidime-avibactam against gram-negative bacteria resistant to carbapenemics in Colombia.
Authors: Muñoz Angulo, Natalia1 (AUTHOR), Arsanios Martín, Daniel2 (AUTHOR) danielmaar@unisabana.edu.co, Cubides Díaz, Diego Alejandro2 (AUTHOR)
Source: Universitas Médica. 2021, Vol. 62 Issue 2, p1-17. 17p.
Abstract (English): Antibiotic resistance is a major public health problem worldwide, because it increases morbidity and mortality to a large number of pathologies, being responsible for 700,000 deaths per year. It is estimated that by 2050 it will account for up to 10 million deaths per year, becoming the leading cause of mortality over cardiovascular disease and cancer. This discouraging panorama has prompted the research on new antimicrobials, some of which, such as ceftazidime-avibactam (CAZ-AVI), have already been introduced into clínical practice. CAZ-AVI is a combination of a third generation cephalosporin and a new non-β-lactam β-lactamase inhibitor active against multidrug-resistant gram-negative bacteria (MDR), which, due to its high efficacy and low incidence of adverse effects, has been approved for the treatment of complicated urinary tract infections, complicated intra-abdominal infections and ventilator-associated pneumonia. A narrative review of the literature was carried out covering the main topics related to this antimicrobial, as well as what has been reported so far in our country. [ABSTRACT FROM AUTHOR]
Abstract (Spanish): En el mundo, la resistencia antibiótica es un gran problema de salud pública, debido a que aumenta la morbimortalidad, por un gran número de patologías. Es responsable de 700.000 muertes por año y que se estima que para el año 2050 puede alcanzar cifras de hasta 10 millones de muertes por año y llegar a ser la primera causa de mortalidad por encima de las enfermedades cardiovasculares y el cáncer. Este panorama desalentador ha impulsado la investigación de nuevos antimicrobianos, algunos de los cuales, como la ceftazidima-avibactam (CAZ-AVI), ya se han introducido en la práctica clínica. La CAZ-AVI es una combinación de una cefalosporina de tercera generación y un nuevo inhibidor de β-lactamasa activo contra bacterias gramnegativas multidrogorresistentes que, por su gran eficacia y baja incidencia de efectos adversos, ha sido aprobada para el tratamiento de infecciones complicadas de las vías urinarias, infecciones intrabdominales complicadas y neumonías asociadas al ventilador. Esta es una revisión narrativa de la literatura que abarca los principales temas relacionados con este antimicrobiano, así como lo reportado hasta el momento en nuestro país. [ABSTRACT FROM AUTHOR]
Copyright of Universitas Médica is the property of Pontificia Universidad Javeriana and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: lth
DbLabel: MedicLatina
An: 155437797
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Nicho terapéutico de ceftazidima-avibactam frente a bacterias gramnegativas resistentes a carbapenémicos en Colombia.
– Name: TitleAlt
  Label: Alternate Title
  Group: TiAlt
  Data: Therapeutic niche of ceftazidime-avibactam against gram-negative bacteria resistant to carbapenemics in Colombia.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Muñoz+Angulo%2C+Natalia%22">Muñoz Angulo, Natalia</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Arsanios+Martín%2C+Daniel%22">Arsanios Martín, Daniel</searchLink><relatesTo>2</relatesTo> (AUTHOR)<i> danielmaar@unisabana.edu.co</i><br /><searchLink fieldCode="AR" term="%22Cubides+Díaz%2C+Diego+Alejandro%22">Cubides Díaz, Diego Alejandro</searchLink><relatesTo>2</relatesTo> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Universitas+Médica%22">Universitas Médica</searchLink>. 2021, Vol. 62 Issue 2, p1-17. 17p.
– Name: Abstract
  Label: Abstract (English)
  Group: Ab
  Data: Antibiotic resistance is a major public health problem worldwide, because it increases morbidity and mortality to a large number of pathologies, being responsible for 700,000 deaths per year. It is estimated that by 2050 it will account for up to 10 million deaths per year, becoming the leading cause of mortality over cardiovascular disease and cancer. This discouraging panorama has prompted the research on new antimicrobials, some of which, such as ceftazidime-avibactam (CAZ-AVI), have already been introduced into clínical practice. CAZ-AVI is a combination of a third generation cephalosporin and a new non-β-lactam β-lactamase inhibitor active against multidrug-resistant gram-negative bacteria (MDR), which, due to its high efficacy and low incidence of adverse effects, has been approved for the treatment of complicated urinary tract infections, complicated intra-abdominal infections and ventilator-associated pneumonia. A narrative review of the literature was carried out covering the main topics related to this antimicrobial, as well as what has been reported so far in our country. [ABSTRACT FROM AUTHOR]
– Name: Abstract
  Label: Abstract (Spanish)
  Group: Ab
  Data: En el mundo, la resistencia antibiótica es un gran problema de salud pública, debido a que aumenta la morbimortalidad, por un gran número de patologías. Es responsable de 700.000 muertes por año y que se estima que para el año 2050 puede alcanzar cifras de hasta 10 millones de muertes por año y llegar a ser la primera causa de mortalidad por encima de las enfermedades cardiovasculares y el cáncer. Este panorama desalentador ha impulsado la investigación de nuevos antimicrobianos, algunos de los cuales, como la ceftazidima-avibactam (CAZ-AVI), ya se han introducido en la práctica clínica. La CAZ-AVI es una combinación de una cefalosporina de tercera generación y un nuevo inhibidor de β-lactamasa activo contra bacterias gramnegativas multidrogorresistentes que, por su gran eficacia y baja incidencia de efectos adversos, ha sido aprobada para el tratamiento de infecciones complicadas de las vías urinarias, infecciones intrabdominales complicadas y neumonías asociadas al ventilador. Esta es una revisión narrativa de la literatura que abarca los principales temas relacionados con este antimicrobiano, así como lo reportado hasta el momento en nuestro país. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Universitas Médica is the property of Pontificia Universidad Javeriana and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=155437797
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.11144/Javeriana.umed62-2.nich
    Languages:
      – Code: spa
        Text: Spanish
    PhysicalDescription:
      Pagination:
        PageCount: 17
        StartPage: 1
    Titles:
      – TitleFull: Nicho terapéutico de ceftazidima-avibactam frente a bacterias gramnegativas resistentes a carbapenémicos en Colombia.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Muñoz Angulo, Natalia
      – PersonEntity:
          Name:
            NameFull: Arsanios Martín, Daniel
      – PersonEntity:
          Name:
            NameFull: Cubides Díaz, Diego Alejandro
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: 2021
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-print
              Value: 00419095
          Numbering:
            – Type: volume
              Value: 62
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Universitas Médica
              Type: main
ResultId 1